Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Rund 40 Mio. USD Staatsaufträge bis Juni 2029 gebucht: Jetzt zählt die Marge!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
AB

WKN: A40YEP | ISIN: CA03835T4081 | Ticker: N/A
Frankfurt
03.07.26 | 08:00
1,440 Euro
0,00 % 0,000
1-Jahres-Chart  (nicht börsennotiert)
APTOSE BIOSCIENCES INC Chart 1 Jahr

Aktuelle News zur APTOSE BIOSCIENCES

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
APTOSE BIOSCIENCES Aktie jetzt für 0€ handeln
16.07.XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 16.07.2026611The following instruments on Boerse Frankfurt do have their last trading day on 16.07.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 16.07.2026ISIN NameCA03835T4081 APTOSE...
► Artikel lesen
06.07.XFRA LTI0: AUSSETZUNG/SUSPENSION303DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAPTOSE BIOSCI.JAN...
► Artikel lesen
06.07.XFRA CAPITAL ADJUSTMENT INFORMATION - 06.07.2026610Das Instrument 6ZR SE0015988100 MOVEBYBIKE EUROPE AB EQUITY wird cum Kapitalmassnahme gehandelt am 06.07.2026 und ex Kapitalmassnahme am 07.07.2026 The instrument 6ZR SE0015988100 MOVEBYBIKE EUROPE...
► Artikel lesen
03.07.Aptose Biosciences Inc (4): Aptose Biosciences to be delisted from TSX July 31
01.07.Aptose Biosciences Inc. - 15-12G, Securities registration termination1
01.07.Aptose Biosciences, Inc.: Aptose Biosciences Announces Completion of Acquisition by Hanmi Pharmaceutical251SAN DIEGO and TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib...
► Artikel lesen
16.06.Aptose Biosciences Inc (4): Aptose releases AML triplet response data at EHA1
15.06.Aptose Biosciences Inc. - 8-K, Current Report1
15.06.Aptose Biosciences reports 86% response rate in AML triplet therapy trial4
15.06.Aptose Biosciences, Inc.: Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation1
29.05.Aptose Biosciences Inc (4): Aptose working to close Hanmi arrangement in June1
29.05.Aptose Biosciences Inc. - 8-K, Current Report1
29.05.Aptose Biosciences, Inc.: Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical336SAN DIEGO and TORONTO, May 29, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF) announced today that closing of the previously announced arrangement...
► Artikel lesen
13.05.Aptose Biosciences, Inc.: Aptose Reports First Quarter 2026 Results433SAN DIEGO and TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib...
► Artikel lesen
30.04.Aptose Biosciences, Inc.: Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi Pharmaceutical270SAN DIEGO and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF) announced today that closing of the previously announced arrangement...
► Artikel lesen
31.03.Aptose Biosciences, Inc.: Aptose Biosciences Announces Results of Special Shareholders Meeting; Announces Receipt of Final Court Approval of Plan of Arrangement; Reports Year End 2025 Results and Corporate Highlights932Shareholders approve acquisition of Aptose by Hanmi Pharmaceutical in "Go Private" transaction TUS+VEN+AZA triplet frontline therapy continues to demonstrate favorable safety and high rates of efficacy...
► Artikel lesen
19.12.25Aptose Biosciences, Inc.: Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC400SAN DIEGO and TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF) announced today that it will be rescheduling its upcoming special...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten